Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

LIFITEGRAST

LIFITEGRAST

Standard Dose
5%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LIFITEGRAST is listed in Drugs@FDA under application 215126 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LIFITEGRAST Form and strength SOLUTION/DROPS;OPHTHALMIC - 5% Sponsor SUN PHARM INDS LTD Submission history Latest submission status date: 2023-01-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview LIFITEGRAST is listed in Drugs@FDA under application 215126 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LIFITEGRAST Form and strength SOLUTION/DROPS;OPHTHALMIC - 5% Sponsor SUN PHARM INDS LTD Submission history Latest submission status date: 2023-01-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.